ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Jubilant, Wistar Institute to Evaluate Novel PAD4 Inhibitors to Reduce Severity of COVID-19
January 25, 2021Jubilant Therapeutics has announced a collaboration with The Wistar Institute to evaluate the ability of Peptidyl Arginine Deiminase 4 (PAD4) inhibitors provided by Jubilant Therapeutics to block neutrophil extracellular trap (NET) formation in the ... -
Jubilant Therapeutics, The Wistar Institute to collaborate on COVID-19 research
January 18, 2021To evaluate the activity of novel PAD4 inhibitors to reduce clinical severity of COVID-19.
Pharma Sources Insight January 2025
